jump to navigation

Israel Life Science M&As and IPOs totaled $736 million in 2006 May 17, 2007

Posted by israelhealthcare in Life Science.
Tags: , ,
add a comment

The number of Mergers & Acquisitions (M&As) and IPOs of Israeli life sciences companies totaled $736 million in 2006. This amount accounts for 7.4% of total M&As carried out by Israeli technology companies in 2006. According to a new survey held by IVC Research Center towards the Biomed Israel 2007 Week.

Nine life science companies raised $85 million in IPOs carried out in stock exchanges in the USA, Europe, Asia and Israel, which accounts for 12.3% of the IPOs of all high tech companies in Israel. 41% of the IPOs of life science companies were of medical instrumentation companies. The survey also reveals that 77 new life science companies were established from the beginning of 2006.

“2007 figures testify for an increase in the scope of IPOs by life science companies as compared with 2006, said Efrat Zakai, IVC’s research manager. ”From the beginning of the year, companies issued shares at total value of $145 million. The three most prominent IPOs were of BioLineRX and Itamar Medical, which were issued at the Tel Aviv Stock Exchange, and Rosetta Genomics, which was issued at NASDAQ at $30.2 million.”

Sponsored Links – Medical Compression Device | Olive Oil Baby Skin Care

NovaThera and Gamida Cell collaborate to develop cell therapeutics for lung disease May 11, 2007

Posted by israelhealthcare in Cell Therapeutics.
Tags: ,
add a comment

NovaThera and Gamida Cell signed a collaboration agreement aimed at developing cell therapeutic treatments for lung repair and regeneration. The two companies will pool technology and expertise and work together with the clinical team at Papworth Hospital in the UK towards advancing cell therapy approaches for treating lung disease.

NovaThera specializes in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions.

Gamida Cell develops therapeutics using proprietary technologies that expand populations of hematopoietic stem/progenitor cells such as those derived from cord blood for the treatment of hematological diseases as well as for tissue regeneration applications.

“This is a very exciting development, and could be a huge step towards a practical approach to the regeneration and repair of lungs severely damaged by incurable diseases such as emphysema and smoking,” said Dame Professor Julia Polak, from the Imperial College London and a world expert in the field of lung pathology.

Lung disease is a major killer and the cause of chronic illness in the western world. Research indicates that considerable advances in treating lung disease could come from using stem cells to repair and regenerate damaged tissues.

Sponsored Links – Medical Application Testing Management Software | Natural Skin Care Products | Home ECG Monitoring Device